at CNBC.com (Feb 28, 2014)
Endologix (ELGX +0.5%) receives premarket FDA approval for a broadened indication of it's 21Fr profile and smaller EVAR systems, including totally percutaneous endovascular aneurysm repair. The authorization is based on the successful outcome of it's first clinical trial, the PEVAR Trial.
From other sites
at CNBC.com (Dec 5, 2013)
at MarketWatch.com (May 1, 2012)
at MarketWatch.com (Feb 23, 2011)